ArticleF1000Research2025
Assessing the Role of lncRNA GAS5 in Thyroid Function Regulation and Their Potential Use as Biomarkers for Hyperthyroidism Management.
Article in F1000Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long non-coding RNAs (lncRNAs) are increasingly recognized as important regulators of cellular processes, including those implicated in autoimmune and endocrine disorders. However, their role in thyroid function, particularly hyperthyroidism, remains insufficiently defined. Growth Arrest-Specific 5 (GAS5) is a lncRNA with established functions in tumor suppression, cell cycle arrest, and apoptosis, and may therefore influence thyroid cell regulation and hormone production. This study aimed to assess the expression of GAS5 in patients with hyperthyroidism and evaluate its potential utility as a biomarker. Thirty whole-blood samples from hyperthyroid patients and 20 samples from healthy controls were analyzed. Total RNA was extracted using Trizol, and complementary DNA (CDNA) was synthesized with oligo(dT) primers. GAS5 expression was quantified by qRT-PCR, and statistical analysis was performed using One-Way ANOVA, correlation testing, and visualization in R. GAS5 expression was significantly decreased in hyperthyroid patients compared with controls (mean 0.429 vs. 1.004,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.